myokardia myokardia inc is pioneering a precision medicine approach to discover develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases our initial focus is on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction  about cardiomyopathies heartbeats a conversation with the hypertrophic cardiomyopathy experts listen to the podcast news  events may   myokardia reports first quarter  financial results and operational progress link april   myokardia appoints david meeker md to board of directors link march   myokardia appoints kim popovits and wendy yarno to board of directors link march   myokardia reports fourth quarter and full year  financial results and operational progress link february   first subjects dosed in myokardia phase  study of dilated cardiomyopathy candidate myk link myokardia leadership about us mission  values in the news founders leadership board of directors leadership tassos gianakakos chief executive officer tassos gianakakos joined myokardia in october  bringing more than  years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company he joined myokardia from map pharmaceuticals acquired by allergan in march  where he was most recently senior vice president and chief business officer in this position mr gianakakos played an integral role in advancing the company’s two phase  clinical programs and regulatory filings for levadex® and led the successful copromotion partnership agreement for the program with allergan as well as a global partnership with astrazeneca for the company’s unit dose budesonide program prior to map mr gianakakos led the formation of codexis inc a spinoff of maxygen inc in  at codexis mr gianakakos served as president and senior vice president business development and global head of codexis pharmaceuticals business unit before forming codexis mr gianakakos was director of business development at maxygen where he led the company’s business development efforts for its vaccine and bioindustrial platforms as well as financing activities including the company’s initial public offering prior to maxygen mr gianakakos was a process engineer in merck  co’s vaccine division mr gianakakos holds bsc degrees in chemical engineering and economics from the massachusetts institute of technology an msc in biotechnology from northwestern university and an mba from harvard business school executive committee member marc semigran md chief medical officer marc semigran md joined myokardia as chief medical officer in december  previously he led the massachusetts general hospital heart failure and cardiac transplant program as section head and medical director from  to  in addition he was principal investigator of the harvard regional clinical center of the national heart lung and blood institute heart failure network dr semigran was a member of the internal medicine and cardiology staff of massachusetts general for more than  years and is an associate professor at harvard medical school he has published more than  peerreviewed papers in cardiomyopathy heart failure and cardiac transplantation and served as editor for a leading textbook on heart failure dr semigran is a recipient of numerous national institutes of health and industry research awards and has served as principal or coinvestigator in several major clinical trials across various therapeutic areas in addition he has served in scientific and medical advisory capacities to such companies as gsk medtronic plc and bayer dr semigran earned ab am and md degrees from harvard university he completed his internal medicine residency and cardiology fellowship training at massachusetts general june lee md chief operating officer june lee md has significant experience leading early clinical development programs and is also a recognized leader in academic translational research dr lee is an adjunct professor at the university of california san francisco ucsf school of medicine where she formerly served as director of translational research and director of catalyst program which is an internal accelerator at ucsf for early stages technologies in therapeutics devices diagnostics and digital health a key focus of dr lee’s work was identifying the most compelling discovery research and enabling and supporting its commercialization previously she worked in early clinical development in cardiovascular metabolism respiratory and infectious diseases at genentech dr lee serves as chair of the board of directors for the council of korean americans she is also a member of the translational research advisory council of the mogam research institute and the mtrac for life sciences innovation hub therapeuticdiagnostic oversight committee a unit associated with the university of michigan medical school dr lee completed her undergraduate work in chemistry at the johns hopkins university earned her md degree at the school of medicine at university of california davis and her clinical training in internal medicine and pulmonarycritical care and ucla and ucsf executive committee member jake bauer senior vice president finance  corporate development jake bauer has significant experience in the biopharmaceutical industry bringing senior leadership experience business development and business operations expertise to the company he joined myokardia from ablexis llc where he was vice president business operations and head of corporate development at ablexis he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations ablexis’ alivamab mouse platform is licensed to six of the  global pharmaceutical companies prior to ablexis mr bauer was a principal at third rock ventures where he identified evaluated and developed new opportunities for investment assisted with startup corporate development and operations of portfolio companies and negotiated financings he was actively involved in a variety of leading biopharmaceutical companies including agios cytomx global blood therapeutics and zafgen prior to third rock ventures mr bauer served in roles in the investment group at royalty pharma the business development group at endo pharmaceuticals and was previously a management consultant at putnam associates mr bauer holds a bsc in biology and a ba in economics from duke university and an mba from harvard business school executive committee member ingrid boyes senior vice president human resources ingrid boyes has more than  years of human resources and senior leadership experience across the insurance banking and biotech industries prior to myokardia ms boyes was vice president and head of human resources for global product development at roche in this role she was responsible for leading the human resources strategy globally for that function previously she was at genentech where she held positions of increasing responsibility including director of corporate staffing and diversity she was also senior director of human resources for technical operations and prior to that held a similar role leading human resources for north america commercial operations  ms boyes holds a bs from the university of san francisco and an mba from notre dame de namur university executive committee member   joseph lambing phd senior vice president nonclinical and pharmaceutical development joe lambing phd has more than  years of drug development experience in the areas of cardiovascular disease inflammation and oncology during his career dr lambing has contributed to numerous nda and ind filings for more than a dozen new chemical entities as well as numerous filings to support a variety of clinical trials in other countries prior to joining myokardia he was senior vice president of development for portola pharmaceuticals where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in  prior to portola dr lambing served as director of drug safety and disposition for millennium pharmaceuticals’ san francisco site and director of dmpk and toxicology at cor therapeutics dr lambing holds a bs in chemistry and a phd in biochemistry from the university of missouri and was a postdoctoral fellow at the university of california san diego executive committee member robert s mcdowell phd senior vice president of drug discovery robert mcdowell has  years of experience discovering small molecule drugs in cardiovascular disease inflammation and oncology with seven compounds advancing into clinical trials prior to joining myokardia dr mcdowell led drug discovery at v biosciences advancing the companys lead program into development he previously served as vice president of research at sunesis pharmaceuticals where he oversaw drug discovery translational research and manufacturing functions dr mcdowell led the structural chemistry group at axys pharmaceuticals before joining axys dr mcdowell was a senior scientist at genentech where he developed successful strategies for peptidomimetic design dr mcdowell has authored more than  peerreviewed manuscripts and is an inventor on more than  issued us patents dr mcdowell holds a bs in chemistry and physics from butler university and a phd in chemistry from the university of california at berkeley executive committee member lisa alaimo vice president program team leader lisa alaimo has more than  years of research and development experience across a range of biotech companies managing products at various stages of development ms alaimo currently manages the company’s dilated cardiomyopathy program as well as myokardia’s collaboration with sanofi the alliance of the two companies one of the largest research and development commitments in genetic cardiomyopathy encompasses three major development programs at myokardia ms alaimo has served in project and strategic product development leadership roles at portola pharmaceuticals cor therapeutics and millennium pharmaceuticals  ms alaimo holds a bs in genetics and biochemistry from university of california davis radhika tripuraneni md vice president medical affairs radhika tripuraneni md has more than a decade of experience across multiple therapeutic areas including rare and cardiovascular diseases prior to myokardia dr tripuraneni was vice president medical affairs at synageva biopharma later alexion pharmaceuticals where she worked closely with physicians medical societies and patient groups to further disease awareness and support clinical trial enrollment and execution previously she was a cardiovascular medical director at gilead sciences and served as global medical director and global medical affairs lead for two therapeutic areas at genzyme  dr tripuraneni holds undergraduate degrees in business administration and liberal arts and an md degree from the university of missouri she did her surgical internship at beth israel deaconess medical center in boston a major teaching hospital of harvard medical school she earned a master’s of public health degree from harvard university  myokardia contact myokardia inc  allerton ave south san francisco ca  phone   infomyokardiacom media inquiries steven cooper edelman  stevencooperedelmancom clinical trial or medical inquiries send inquiry educational grants and charitable contributions myokardia is committed to furthering collaborative efforts that bring together researchers the medical community drug developers and the patients whom we all serve to that end we strive to provide support for high quality programs that ultimately drive toward improved patient care myokardia will consider requests for support to advance the knowledge and understanding in the following therapeutic areas hypertrophic cardiomyopathy hcm dilated cardiomyopathy dcm additional areas of clinical or preclinical significance relevant to myokardia to facilitate this process myokardia has established a grant review committee that meets regularly to evaluate all requests for educational grants and charitable donations the following information must be provided with every request completed and signed grant request form programevent objectives and agenda programevent itemized budget w irs c or c tax designation letter if you are interested in submitting a request please email us at corporategivingmyokardiacom to obtain a grant request form or inquire further about funding opportunities funding determinations will be made within  days of receipt of completed application myokardia about us about us mission  values in the news founders leadership board of directors myokardia is pioneering a precision medicine approach to discover develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases our initial focus is on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction  our goal is to be the world’s leading precision cardiovascular medicine company precision medicine involves discovering and developing therapies that integrate clinical and molecular information based on the biological basis of disease this approach has led to the efficient discovery and development of transformative therapies in areas such as oncology cystic fibrosis and hypercholesterolemia but has yet to be broadly applied to cardiovascular diseases we have used our precision medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy or hcm and dilated cardiomyopathy or dcm  there are currently no approved therapies indicated for the treatment of hcm or dcm including heritable dcm all of which are chronic and debilitating diseases patients are typically treated with drugs that are indicated for broader cardiovascular disorders and do not address the underlying cause of the disease as the disease progresses patients have limited treatment options such as surgical or other invasive interventions and heart transplant launched in  by third rock ventures myokardia was founded by worldclass experts in cardiovascular disease cardiac muscle biology and genetics  myokardia careers careers current opportunities benefits if you are ready to help lead a revolution in cardiology and transform the way genetic heart disease is treated myokardia may be the place for you we are currently looking for exceptional candidates who are passionate about breakthrough science and transforming the treatment of genetic heart disease through a personalized medicine approach if you are interested in becoming a member of the myokardia team please visit our current opportunities page our core values patients first passion for science succeed together imagine and innovate lifelong learning   myokardia at a glance pdf myokardia current opportunities careers current opportunities benefits we are currently looking for exceptional candidates who are passionate about breakthrough science and transforming the treatment of genetic heart disease through a personalized medicine approach if you are interested in becoming a member of the myokardia team please select a function below to view the current positions that are open in this area and submit your resume     note to staffing and placement agencies if you are interested in submitting potential candidates for our open positions we ask that you not contact employees or managers directly but rather request that you email your agencyfirm information to myocareersmyokardiacom we will review your information and we will contact you if a need arises to use your services please note that all of our open positions are managed through our human resources department and unsolicited resumes in advance of an agreement in place will not be accepted resumes sent directly to employees or hiring managers will also not be accepted as referrals thanks in advance we look forward to a potential job search collaboration myokardia programs programs discovery pipeline collaborations scientific publications we are pioneering the application of precision medicine to cardiovascular disease with an initial focus on delivering the first approved therapies specifically targeting the underlying causes of heritable cardiomyopathies our initial focus is on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction  in  myokardia forged a strategic worldwide collaboration with sanofi to discover develop and advance firstofitskind targeted therapeutics for hcm and dcm  myokardia is currently evaluting its lead drug candidate myk in multiple clinical trials myokardia inc private company information  bloomberg july    pm et pharmaceuticals company overview of myokardia inc snapshot people company overview myokardia inc a clinical stage biopharmaceutical company engages in discovering developing and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases its lead product candidate is myk an orallyadministered small molecule that is in phase ii clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy hcm the company also develops myk an orallyadministered small molecule that treats genetic dilated cardiomyopathy dcm by restoring normal contractility in the diseased dcm heart in addition it develops hcm a product candidate to reduce cardiac muscle contractility to normal myokardia inc a clinical stage biopharmaceutical company engages in discovering developing and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases its lead product candidate is myk an orallyadministered small molecule that is in phase ii clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy hcm the company also develops myk an orallyadministered small molecule that treats genetic dilated cardiomyopathy dcm by restoring normal contractility in the diseased dcm heart in addition it develops hcm a product candidate to reduce cardiac muscle contractility to normal levels in hcm patients dcm a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic dcm patients through a different mechanism than that of myk and lus a product candidate which is intended to counteract a muscle disruption that results in impaired relaxation of the heart the company has a strategic collaboration with sanofi sa for the research development and commercialization of pharmaceutical products to treat prevent and diagnose hcm and dcm as well as additional indications myokardia inc was founded in  and is headquartered in south san francisco california detailed description  allerton avenuesouth san francisco ca united statesfounded in  employees phone  wwwmyokardiacom key executives for myokardia inc mr tassos anastasios gianakakos chief executive officer president and director age  total annual compensation k mr jake b bauer principal financial officer senior vp of finance  corporate development and assistant secretary age  total annual compensation k dr joseph lambing phd md senior vice president of nonclinical and pharmaceutical development age  total annual compensation k dr robert s mcdowell phd md senior vice president of drug discovery age  total annual compensation k dr marc semigran md chief medical officer age  total annual compensation k compensation as of fiscal year  myokardia inc key developments myokardia inc presents at jmp securities life sciences conference  jun  am jun   myokardia inc presents at jmp securities life sciences conference  jun  am venue st regis hotel  east  street new york new york united states myokardia inc announces unaudited earnings results for the quarter ended march   may   myokardia inc announced unaudited earnings results for the quarter ended march   for the quarter the company reported collaboration and license revenue of  against  a year ago loss from operations was  against  a year ago net loss attributable to common stockholders was  against  a year ago basic and diluted loss per share was  against  a year ago myokardia inc to report q  results on may   may   myokardia inc announced that they will report q  results at  pm eastern standard time on may   similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact myokardia inc please visit wwwmyokardiacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close myokardia inc myoko company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile myokardia inc myoko related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse myoko on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description myokardia inc incorporated on june   is a clinicalstage biopharmaceutical company the company focuses on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction the company is engaged in the business of developing and commercializing therapeutics the company has used its precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathyhypertrophic cardiomyopathy hcm and dilated cardiomyopathy dcm additionally the company has three preclinical programs hcm dcm and lusthe companys lead product candidate myk is an orallyadministered small molecule designed to reduce excessive cardiac muscle contractility leading to hcm the company is enrolling patients in a phase ii clinical trial of myk which is referred as pioneerhcm in three phase  clinical trials the company has observed favorable tolerability of single and multiple doses of myk in both healthy volunteers and hcm patients its myk is an orallyadministered small molecule designed to treat genetic dcm by restoring normal contractility in the diseased dcm heart the company is in a phase  clinical trial of myk its product candidate for the treatment of dcmthe companys precision medicine platform incorporates disease research drug discovery and clinical expertise in a selfreinforcing cycle that enables the iterative generation of new disease targets and clinical development candidates designed to establish early clinical proofofconcept hcm is intended to reduce cardiac muscle contractility to normal levels in hcm patients through a different mechanism than that of myk dcm is intended to increase cardiac muscle contractility to normal levels in genetic dcm patients through a different mechanism than that of myk lus is intended to counteract a muscle disruption that results in impaired relaxation of the heart a biomechanical defect found in specific hcm and genetic dcm patient subgroups as well as in other less common heritable cardiomyopathiesthe company competes with amgen inc bayer ag bristolmyers squibb company ch boehringer sohn ag  co kg gilead sciences inc novartis ag takeda pharmaceutical company limited gilead sciences inc heart metabolics limited array biopharma inc kasiak research pvt ltd vericel corp and zensun shanghai sci tech co ltd » full overview of myoko company address myokardia inc  allerton avesouth san francisco   ca    p f  company web links home page officers  directors name compensation mark perry  tassos gianakakos  june lee  jake bauer  joseph lambing  » more officers  directors myokardia inc news briefmyokardia files for offering of up to  shares of common stock by selling stockholders jul   briefmyokardia qtrly net loss per share   may   briefmyokardia appoints kim popovits wendy yarno to board mar   briefmyokardia q net income  mln mar   briefmyokardia announces appointment of chief operating officer feb   » more myoko news related topics stocksstock screenerhealthcarebiotechnology  medical research myokardia inc company profile bioportfolio biotech healthcare and medical resources advertisement topics all topics biotechnology biotech business biotech products cancer cardiovascular dermatology drug discovery endocrinology gastroenterology immunology infectious diseases mental health neurology obstetrics orthopedics public health respiratory rheumatology urology  track topics on twitter track topics that are important to you printed from bioportfoliocom myokardia inc company profile  edt th july   bioportfolio myokardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease the companyâs proprietary platform combines recent breakthroughs in muscle biology with leadingedge cardiovascular disease genetics this personalized genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically improve the treatment of cardiomyopathies and ultimately a broader spectrum of cardiovascular disease including heart failure founded by world leaders in muscle biology and cardiovascular disease genetics myokardia was launched in  with funding from leading life sciences investor third rock ventures for more information please visit wwwmyokardiacom news articles  associated news articles listed on bioportfolio deals this week myokardia kala pharmaceuticals mesoblast myokardia has announced plans to issue more than nine million shares of its common stock priced at  a share to raise m in gross proceeds myokardia appoints physician executive david meeker to board of directors myokardia named pharmaceutical executive and physician david meeker md to its board of directors on april  myokardia brings hope to hypertrophic cardiomyopathy myokardia does this small biotech stock belong on your buy list myokardia appoints to board of directors   life sciences jobs    myokardias myok ceo tassos gianakakos on q  results  earnings call transcript myokardia myok presents at cowen and company th annual health care conference myokardia inc myok financial and strategic swot analysis review updated  prices from usd  summarymyokardia inc myokardia is a clinical stage biopharmaceutical company that discovers develops and commercializes therapies for the treatment of serious and rare cardiovascular diseases its pr drugs and medications  results none pubmed articles  results none clinical trials  results none companies  associated companies listed on bioportfolio myokardia inc myokardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease the companyâs proprietary platform combines recent breakthroughs in muscle biology  more information about myokardia inc on bioportfolio we have published hundreds of myokardia inc news stories on bioportfolio along with dozens of myokardia inc clinical trials and pubmed articles about myokardia inc for you to read in addition to the medical data news and clinical trials bioportfolio also has a large collection of myokardia inc companies in our database you can also find out about relevant myokardia inc drugs and medications on this site too quick linksadvanced search  login  subscribe  rss quick search advertisement   relevant topics cardiology cardiology is a specialty of internal medicine  cardiac electrophysiology  study of the electrical properties and conduction diseases of the heart echocardiography  the use of ultrasound to study the mechanical functionphysics of the h rheumatology arthritis fibromyalgia gout lupus rheumatic rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints tendons muscles ligaments and associated structures oxford medical diction cardiovascular disease cvd acute coronary syndromes acs blood cardiovascular dialysis hypertension stent stroke vascular cardiovascular disease cvd includes all the diseases of the heart and circulation including coronary heart disease angina corporate database quicklinks search corporate database latest corporate records biotech companies by location popular company records recent company searches add or control your corporate profile searches linking to this company record bioportfolio limited about us contact us social media twitter  accounts twitter google linkedin publish content publish publish your press release advertise agreements agreements medical disclaimer privacy tools mybioportfolio rss help faqs sitemaps xml sitemap this site complies with the honcode standard for trustworthy health information verify here the information provided by bioportfoliocom is not a substitute for professional medical advice diagnosis or treatment the bioportfolio site is sponsored bioportfolio limited with offices at stafford house  prince of wales road dorchester dt pw england if you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “fair use” and legitimately infringes on your or your clients copyright we may be contacted concerning copyright matters at prioritybioportfoliocom all rights reserved all other trademarks recognized copyright   bioportfolio limited site developed by alacrify ltd myokardia inc company profile bioportfolio biotech healthcare and medical resources advertisement topics all topics biotechnology biotech business biotech products cancer cardiovascular dermatology drug discovery endocrinology gastroenterology immunology infectious diseases mental health neurology obstetrics orthopedics public health respiratory rheumatology urology  track topics on twitter track topics that are important to you printed from bioportfoliocom myokardia inc company profile  edt th july   bioportfolio myokardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease the companyâs proprietary platform combines recent breakthroughs in muscle biology with leadingedge cardiovascular disease genetics this personalized genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically improve the treatment of cardiomyopathies and ultimately a broader spectrum of cardiovascular disease including heart failure founded by world leaders in muscle biology and cardiovascular disease genetics myokardia was launched in  with funding from leading life sciences investor third rock ventures for more information please visit wwwmyokardiacom news articles  associated news articles listed on bioportfolio deals this week myokardia kala pharmaceuticals mesoblast myokardia has announced plans to issue more than nine million shares of its common stock priced at  a share to raise m in gross proceeds myokardia appoints physician executive david meeker to board of directors myokardia named pharmaceutical executive and physician david meeker md to its board of directors on april  myokardia brings hope to hypertrophic cardiomyopathy myokardia does this small biotech stock belong on your buy list myokardia appoints to board of directors   life sciences jobs    myokardias myok ceo tassos gianakakos on q  results  earnings call transcript myokardia myok presents at cowen and company th annual health care conference myokardia inc myok financial and strategic swot analysis review updated  prices from usd  summarymyokardia inc myokardia is a clinical stage biopharmaceutical company that discovers develops and commercializes therapies for the treatment of serious and rare cardiovascular diseases its pr drugs and medications  results none pubmed articles  results none clinical trials  results none companies  associated companies listed on bioportfolio myokardia inc myokardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease the companyâs proprietary platform combines recent breakthroughs in muscle biology  more information about myokardia inc on bioportfolio we have published hundreds of myokardia inc news stories on bioportfolio along with dozens of myokardia inc clinical trials and pubmed articles about myokardia inc for you to read in addition to the medical data news and clinical trials bioportfolio also has a large collection of myokardia inc companies in our database you can also find out about relevant myokardia inc drugs and medications on this site too quick linksadvanced search  login  subscribe  rss quick search advertisement   relevant topics cardiology cardiology is a specialty of internal medicine  cardiac electrophysiology  study of the electrical properties and conduction diseases of the heart echocardiography  the use of ultrasound to study the mechanical functionphysics of the h rheumatology arthritis fibromyalgia gout lupus rheumatic rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints tendons muscles ligaments and associated structures oxford medical diction cardiovascular disease cvd acute coronary syndromes acs blood cardiovascular dialysis hypertension stent stroke vascular cardiovascular disease cvd includes all the diseases of the heart and circulation including coronary heart disease angina corporate database quicklinks search corporate database latest corporate records biotech companies by location popular company records recent company searches add or control your corporate profile searches linking to this company record bioportfolio limited about us contact us social media twitter  accounts twitter google linkedin publish content publish publish your press release advertise agreements agreements medical disclaimer privacy tools mybioportfolio rss help faqs sitemaps xml sitemap this site complies with the honcode standard for trustworthy health information verify here the information provided by bioportfoliocom is not a substitute for professional medical advice diagnosis or treatment the bioportfolio site is sponsored bioportfolio limited with offices at stafford house  prince of wales road dorchester dt pw england if you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “fair use” and legitimately infringes on your or your clients copyright we may be contacted concerning copyright matters at prioritybioportfoliocom all rights reserved all other trademarks recognized copyright   bioportfolio limited site developed by alacrify ltd myokardia inc  myok  stock price today  zacks myok is up  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more myokardia inc myok delayed data from nsdq  usd     updated jul    pm et add to portfolio zacks rank hold          style scores d value  c growth  f momentum  f vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for myok all zacks’ analyst reports news for myok zacks news for myok other news for myok no data available myokardia brings hope to hypertrophic cardiomyopathy am est seeking alpha myokardia brings hope to hypertrophic cardiomyopathy patients am est talkmarkets myokardia inc a new approach in cardiomyopathy treatment am est smarter analyst myokardia does this small biotech stock belong on your buy list am est seeking alpha myokardia reports q loss pm est associated press the more other news for myok premium research for myok zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores d value  c growth  f momentum  f vgm earnings esp  research report for myok snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank myokardia inc myok agenus inc agen bioverativ inc bivv enzo biochem inc enz exact sciences corporation exas exelixis inc exel vertex pharmaceuticals incorporated vrtx see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary myokardia inc is a biopharmaceutical company the company focuses on discovering developing and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases its product candidate consists of myk a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy dcm treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased dcm heart hcm a product candidate to reduce cardiac muscle contractility to normal levels in hcm patients and lus which is intended to counteract a muscle disruption that results in impaired relaxation of the heart which are in different clinical trial myokardia inc is headquartered in san francisco california myok  stocks price quote for myokardia inc cm st your browser of choice has not been tested for use with barchartcom if you have issues please download one of the browsers listed here market data  bb solutions report a bug give feedback market market us canada uk australia financial technology  market data market data feeds ondemand web apis website solutions barchart trader mobile solutions isv solutions content overview enterprise data management edm agribusiness technology solutions     no matching results advanced search or select a commodity wheat corn soybeans soybean meal soybean oil oats rough rice hard red wheat spring wheat canola us dollar index british pound canadian dollar japanese yen swiss franc euro fx australian dollar mexican peso new zealand dollar south african rand brazilian real russian ruble crude oil wti ulsd ny harbor gasoline rbob natural gas crude oil brent ethanol tbond ultra tbond  year tnote  year tnote  year tnote  day fed funds eurodollar sp  emini nasdaq  emini dow indu emini russell  emini sp midcap emini sp  vix sp gsci live cattle feeder cattle lean hogs class iii milk gold silver high grade copper platinum palladium cotton  orange juice coffee sugar  cocoa lumber ice crude oil brent ice crude oil wti ice gas oil ice natural gas ice rbob blendstock ice heating oil euro bund euro bobl euro schatz euro buxl euro oat longterm euro btp longterm eurex conf longterm euro bono longterm year long gilt month euribor month sterling month euroswiss rapeseed feed wheat milling wheat corn euro stoxx  index ftse  index dax index swiss market index cac  index aex index bel  psi  ibex mini omx swedish index vstoxx mini steel scrap steel rebar cocoa  coffee robusta t sugar white  stocks stocks market pulse market overview market momentum market performance top  stocks todays price surprises new highs  lows economic overview earnings within  days earnings  dividends stock screener performance leaders percent change price change range change gap up  gap down five day gainers most active volume leaders price volume leaders volume advances trading liquidity indices major indices sp indices sp sectors dow indices nasdaq index russell indices volatility indices commodities indices us sectors indices trading signals new recommendations top stocks to own top signal strength top signal direction stock signal upgrades sectors major market sectors industry rankings industry performance futures futures market pulse market overview long term trends todays price surprises highs  lows futures market map performance leaders most active futures prices by exchange commitment of traders commodity groupings major commodities currencies energies financials grains indices meats metals softs trading signals new recommendations resources contract specifications futures expirations first notice dates options expirations european futures long term trends todays price surprises highs  lows futures market map performance leaders most active futures european groupings major commodities energies financials grains indices metals softs forex forex market pulse market overview long term trends todays price surprises highs  lows forex market map performance leaders currency groupings major cross rates australian dollar british pound canadian dollar euro fx japanese yen swiss franc us dollar metals rates all forex markets trading signals new recommendations resources currency converter options options market pulse market overview unusual options activity most active options highest implied volatility change in volatility change in open interest volume leaders advanced groupings covered calls naked puts bull call spreads bear call spreads bear put spreads bull put spreads optionable stocks upcoming earnings stocks by sector etfs  funds etfs  funds market pulse market overview major etfs etfs by asset class top  etfs todays price surprises new highs  lows etfs screener performance leaders percent change price change range change gap up  gap down five day gainers most active volume leaders price volume leaders volume advances trading signals new recommendations top etfs to own top signal strength top signal direction etfs signal upgrades mutual funds todays price surprises new highs  lows performance price change funds screener news news market pulse news overview top stories forex news options news futures commentary all sectors currencies energies financials grains indices meats metals softs news by sector aerospace agriculture business services construction consumer products corporate economy energy  oil finance and banking industrial products leisure  recreation media medical retail sales technology  computers transportation utilities barchart exclusive van meerten stock picks chart of the day barchart morning call featured sources zacks news brugler ag report my barchart my barchart my barchart tools my barchart watchlist portfolio portfolio summary alerts manage tools organize watchlists organize portfolios organize screeners custom views chart templates account my profile site preferences subscriptions endofday watchlists endofday portfolios endofday reports barchart newsletters barchart premier premium services barchart premier access a cleaner faster browsing experience of barchartcom with tools and services exclusive to premier members learn more trends in futures learn how to analyze long term trends with trader and barcharts chief market strategist gary kamen learn more barchart trader trade from your desktop tablet or phone with our realtime trading software learn more futures trading education launch your own greatest business on earth by following seasoned trader jim prince as he breaks down best ways to trade commodities learn more menu quotes overview performance report charts interactive chart technical chart  technicals technical analysis traders cheat sheet barchart opinion trading strategies price history company news profile sec filings competitors stock comparison analysts earnings estimates analyst ratings financials income statement cash flow balance sheet   myokardia inc cm st myok  itemlastprice   itempricechange   itempercentchange   itemtradetime  nasdaq  itembidprice  x  itembidsize   itemaskprice  x  itemasksize   session  by bats  itemlastprice   itempricechange   itempercentchange   itemtradetime  nasdaq  itembidprice  x  itembidsize   itemaskprice  x  itemasksize   session   itemlastpriceext   itempricechangeext   itempercentchangeext   itemtradetimeext  quote overview for  itemsessiondatedisplaylong  go to select page performance report interactive chart technical chart technical analysis traders cheat sheet barchart opinion trading strategies price history news profile sec filings competitors stock comparison earnings estimates analyst ratings income statement cash flow balance sheet set alerts watchlist trade with  rowchartdatalabellow   rowchartdatalowpriceformatted   rowchartdatalowprice   rowchartdatalabelhigh   rowchartdatahighpriceformatted   rowchartdatahighprice  since  rowchartdatalowdate  since  rowchartdatahighdate   fieldtitleskey   value   value   ctrlcharttitle  full chart fundamentals see more market capitalization k  shares outstanding k  annual sales   k annual income   k month beta  pricesales  pricecash flow  pricebook  priceearnings ttm  earnings per share ttm  most recent earnings  on  next earnings date  annual dividend  yield   most recent dividend na on na sectors sic pharmaceutical preparations medical  biomedical price performance see more period period low period high performance month   on    on    since  month   on    on    since  week   on    on    since   most recent stories more news myokardia reports first quarter  financial results and operational progress globenewswire  tue may  pm cdt cmtx tue may  pm cdt company to host conference call and webcast today at  pm pt  pm et myok    investor network myokardia inc to host earnings call accesswire  tue may  pm cdt cmtx tue may  pm cdt new york ny  accesswire  may    myokardia inc nasdaq myok will be discussing their earnings results in their q earnings call to be held may   at  pm eastern time myok    myokardia to announce first quarter  financial results and host conference call on tuesday may   globenewswire  tue may  am cdt cmtx tue may  am cdt myokardia inc nasdaqmyok a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases today announced that it will report myok    myokardia appoints david meeker md to board of directors globenewswire  tue apr  am cdt cmtx tue apr  am cdt myokardia inc nasdaqmyok a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases today announced the appointment myok    myokardia appoints kim popovits and wendy yarno to board of directors globenewswire  fri mar  am cdt cmtx fri mar  am cdt myokardia inc nasdaqmyok a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases today announced the appointments myok    first subjects dosed in phase  study of dilated cardiomyopathy candidate myk globenewswire  thu feb  am cst cmtx thu feb  am cst second clinical candidate generated by myokardias product engine myok    myokardia announces appointment of june lee md as chief operating officer and radhika tripuraneni md as vice president medical affairs globenewswire  wed feb  am cst cmtx wed feb  am cst myokardia inc nasdaqmyok a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases today announced the appointment myok    more news for this symbol barchart technical opinion strong buy the barchart technical opinion rating is a  buy and ranks in the top  of all short term signal directions longer term the trend strength is in the top  long term indicators fully support a continuation of the trend the market is approaching overbought territory be watchful of a trend reversal see more get api access to myok quotes  myok related etfs symbol holdings m chg myok  myokardia inc cm st iwm   russell  ishares iwo   russell  growth ishares vti   total stock market etf vanguard iwc   russell microcap ishares vht   healthcare etf vanguard symbol holdings m chg myok  myokardia inc cm st urty   ultrapro russell  proshares twok   russell  etf spdr vxf   extended market index etf vanguard vht   healthcare etf vanguard vtwo   russell  vanguard business summary myokardia inc is a biopharmaceutical company the company focuses on discovering developing and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases its product candidate consists of myk a small molecule to reduce excessive cardiac muscle contractility see more  myok related stocks symbol m chg myok  myokardia inc cm st amgn  amgen celg  celgene corp gild  gilead sciences inc biib  biogen inc regn  regeneron pharmaceutical compare symbols support  resistance nd resistance point  st resistance point  last price  st support level  nd support level  see more log in or sign up log out market market us canada uk australia home stocks market pulse market overview market momentum market performance top  stocks todays price surprises new highs  lows economic overview earnings within  days earnings  dividends stock screener performance leaders percent change price change range change gap up  gap down five day gainers most active volume leaders price volume leaders volume advances trading liquidity indices major indices sp indices sp sectors dow indices nasdaq index russell indices volatility indices commodities indices us sectors indices trading signals new recommendations top stocks to own top signal strength top signal direction stock signal upgrades sectors major market sectors industry rankings industry performance futures market pulse market overview long term trends todays price surprises highs  lows futures market map performance leaders most active futures prices by exchange commitment of traders commodity groupings major commodities currencies energies financials grains indices meats metals softs trading signals new recommendations resources contract specifications futures expirations first notice dates options expirations european futures long term trends todays price surprises highs  lows futures market map performance leaders most active futures european groupings major commodities energies financials grains indices metals softs forex market pulse market overview long term trends todays price surprises highs  lows forex market map performance leaders currency groupings major cross rates australian dollar british pound canadian dollar euro fx japanese yen swiss franc us dollar metals rates all forex markets trading signals new recommendations resources currency converter options market pulse market overview unusual options activity most active options highest implied volatility change in volatility change in open interest volume leaders advanced groupings covered calls naked puts bull call spreads bear call spreads bear put spreads bull put spreads optionable stocks upcoming earnings stocks by sector etfs  funds market pulse market overview major etfs etfs by asset class top  etfs todays price surprises new highs  lows etfs screener performance leaders percent change price change range change gap up  gap down five day gainers most active volume leaders price volume leaders volume advances trading signals new recommendations top etfs to own top signal strength top signal direction etfs signal upgrades mutual funds todays price surprises new highs  lows performance price change funds screener news market pulse news overview top stories forex news options news futures commentary all sectors currencies energies financials grains indices meats metals softs news by sector aerospace agriculture business services construction consumer products corporate economy energy  oil finance and banking industrial products leisure  recreation media medical retail sales technology  computers transportation utilities barchart exclusive van meerten stock picks chart of the day barchart morning call featured sources zacks news brugler ag report my barchart tools my barchart watchlist portfolio portfolio summary alerts manage tools organize watchlists organize portfolios organize screeners custom views chart templates account my profile site preferences subscriptions endofday watchlists endofday portfolios endofday reports barchart newsletters barchart premier bb solutions market data feeds ondemand web apis website solutions barchart trader mobile solutions isv solutions enterprise data management edm agribusiness technology solutions report a bug give feedback quote overview the quote overview page gives you a snapshot view for a specific symbol realtime prices are provided by bats exchange on individual us equities quote pages during market hours the realtime bats price displays and new trade updates are updated on the page as indicated by a flash volume always reflects consolidated markets if the symbol has premarket or postmarket trades that information will also be reflected along with the last closing price from the symbols exchange realtime prices are available during market hours  am to  pm est note the bats exchange currently accounts for approximately  of all us equity trading each day as a result the realtime prices displayed may have minor discrepancies when comparing the information with other sites offering realtime data or with brokerage firms if you require comprehensive realtime bidsasksquotes we offer a norisk trial to one of our realtime products summary quoteboard the summary quoteboard displays snapshot quote data when available bid and ask information from the bats exchange is updated as new data is received volume is also updated but is the delayed consolidated volume from the symbols exchange quoteboard data fields include day high  low the highest and lowest trade price for the current trading session open the opening price for the current trading session is plotted on the days highlow histogram previous close the closing price from the previous trading session bid the last bid price and bid size ask the last ask price and ask size volume the total number of shares or contracts traded in the current trading session average volume the average number of shares traded over the last  days weighted alpha a measure of how much a stock or commodity has risen or fallen over a oneyear period barchart takes this alpha and weights this assigning more weight to recent activity and less  factor to activity at the beginning of the period thus weighted alpha is a measure of oneyear growth with an emphasis on the most recent price activity chart snapshot a thumbnail of a daily chart is provided with a link to open and customize a fullsized chartbarchart technical opinion the barchart technical opinion widget shows you todays overally barchart opinion with general information on how to interpret the short and longer term signals unique to barchartcom opinions analyzes a stock or commodity using  popular analytics in short medium and longterm periods results are interpreted as buy sell or hold signals each with numeric ratings and summarized with an overall percentage buy or sell rating after each calculation the program assigns a buy sell or hold value with the study depending on where the price lies in reference to the common interpretation of the study for example a price above its moving average is generally considered an upward trend or a buy a symbol will be given one of the following overall ratings strong buy greater than  buy buy greater than or equal to  buy and less than or equal to  buy weak buy  buy through  buy hold strong sell greater than  sell sell greater than or equal to  sell and less than or equal to  sell weak sell  sell through  sell the current reading of the day stochastic indicator is also factored into the interpretation the following information will appear when the following conditions are met if the day stochastic k is greater than  and the overall opinion is a buy the following displays the market is in highly overbought territory beware of a trend reversal if the day stochastic k is greater than  and the overall opinion is a buy the following displays the market is approaching overbought territory be watchful of a trend reversal if the day stochastic k is less than  and the overall opinion is a sell the following displays the market is in highly oversold territory beware of a trend reversal if the day stochastic k is less than  and the overall opinion is a sell the following displays the market is approaching oversold territory be watchful of a trend reversal business summary provides a general description of the business conducted by this company price performance this section shows the highs and lows over the past   and month periods click the see more link to see the full performance report page with expanded historical informationfundamentals for us stocks the overview page includes key statistics on the stocks fundamentals with a link to see more most recent earnings figures are based on nongaap income from continuing operations market cap capitalization or market value of a stock is simply the market value of all outstanding shares it is computed by multiplying the market price by the number of outstanding shares for example a publicly held company with  million shares outstanding that trade at  each would have a market capitalization of  million shares outstanding common shares outstanding as reported by the company on the q or k pe ratio latest closing price divided by the earningspershare based on the latest month eps change ltm of earnings companies with negative earnings receive an ne eps the basic annual eps from total operations is the bottom line income after all expenses divided by the weighted average number of common shares outstanding for example if a company has  million in net income and  million in outstanding shares then its eps is  beta  month beta coefficient that measures the volatility of a stocks returns relative to the market sp  it is based on a month historical regression of the return on the stock onto the return on the sp  earnings the amount of latest earnings per share eps paid out to shareholders dividend yield a portion of a companys profit paid to shareholders quoted as the dollar amount each share receives dividends per share yield is the amount of dividends paid per share divided by the closing price sectors links to the industry groups andor sic codes in which the stock is foundsupport and resistance this section shows a snapshot view of the traders cheat sheet with the last price and four separate pivot points  support levels and  resistance points the last price shown is the last trade price at the time the quote page was displayed and will not update every  seconds as the last price at the top of the quote page does the last price will update only when the page is refreshed pivot points are used to identify intraday support resistance and target levels the pivot point and its support and resistance pairs are defined as follows where h l c are the current days high low and close respectively support and resistance points are based on endofday prices and are intended for the current trading session if the market is open or the next trading session if the market is closed pivot point p  h  l  c   first resistance level r    p  l first support level s    p  h second resistance level r  p  r  s second support level s  p  r  s related stocks for comparison purposes find information on other symbols contained in the same sectormost recent stories view the latest top stories from the associated press or canadian press based on your market selection recent commentary  twitter see what others are saying about this symbol on selected financial twitter feeds add data columns to this table learn about our custom views want to use this as your default charts setting learn about our custom templates switch the market flag above for targeted data open the menu and switch the market flag for targeted data myokardia leadership about us mission  values in the news founders leadership board of directors leadership tassos gianakakos chief executive officer tassos gianakakos joined myokardia in october  bringing more than  years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company he joined myokardia from map pharmaceuticals acquired by allergan in march  where he was most recently senior vice president and chief business officer in this position mr gianakakos played an integral role in advancing the company’s two phase  clinical programs and regulatory filings for levadex® and led the successful copromotion partnership agreement for the program with allergan as well as a global partnership with astrazeneca for the company’s unit dose budesonide program prior to map mr gianakakos led the formation of codexis inc a spinoff of maxygen inc in  at codexis mr gianakakos served as president and senior vice president business development and global head of codexis pharmaceuticals business unit before forming codexis mr gianakakos was director of business development at maxygen where he led the company’s business development efforts for its vaccine and bioindustrial platforms as well as financing activities including the company’s initial public offering prior to maxygen mr gianakakos was a process engineer in merck  co’s vaccine division mr gianakakos holds bsc degrees in chemical engineering and economics from the massachusetts institute of technology an msc in biotechnology from northwestern university and an mba from harvard business school executive committee member marc semigran md chief medical officer marc semigran md joined myokardia as chief medical officer in december  previously he led the massachusetts general hospital heart failure and cardiac transplant program as section head and medical director from  to  in addition he was principal investigator of the harvard regional clinical center of the national heart lung and blood institute heart failure network dr semigran was a member of the internal medicine and cardiology staff of massachusetts general for more than  years and is an associate professor at harvard medical school he has published more than  peerreviewed papers in cardiomyopathy heart failure and cardiac transplantation and served as editor for a leading textbook on heart failure dr semigran is a recipient of numerous national institutes of health and industry research awards and has served as principal or coinvestigator in several major clinical trials across various therapeutic areas in addition he has served in scientific and medical advisory capacities to such companies as gsk medtronic plc and bayer dr semigran earned ab am and md degrees from harvard university he completed his internal medicine residency and cardiology fellowship training at massachusetts general june lee md chief operating officer june lee md has significant experience leading early clinical development programs and is also a recognized leader in academic translational research dr lee is an adjunct professor at the university of california san francisco ucsf school of medicine where she formerly served as director of translational research and director of catalyst program which is an internal accelerator at ucsf for early stages technologies in therapeutics devices diagnostics and digital health a key focus of dr lee’s work was identifying the most compelling discovery research and enabling and supporting its commercialization previously she worked in early clinical development in cardiovascular metabolism respiratory and infectious diseases at genentech dr lee serves as chair of the board of directors for the council of korean americans she is also a member of the translational research advisory council of the mogam research institute and the mtrac for life sciences innovation hub therapeuticdiagnostic oversight committee a unit associated with the university of michigan medical school dr lee completed her undergraduate work in chemistry at the johns hopkins university earned her md degree at the school of medicine at university of california davis and her clinical training in internal medicine and pulmonarycritical care and ucla and ucsf executive committee member jake bauer senior vice president finance  corporate development jake bauer has significant experience in the biopharmaceutical industry bringing senior leadership experience business development and business operations expertise to the company he joined myokardia from ablexis llc where he was vice president business operations and head of corporate development at ablexis he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations ablexis’ alivamab mouse platform is licensed to six of the  global pharmaceutical companies prior to ablexis mr bauer was a principal at third rock ventures where he identified evaluated and developed new opportunities for investment assisted with startup corporate development and operations of portfolio companies and negotiated financings he was actively involved in a variety of leading biopharmaceutical companies including agios cytomx global blood therapeutics and zafgen prior to third rock ventures mr bauer served in roles in the investment group at royalty pharma the business development group at endo pharmaceuticals and was previously a management consultant at putnam associates mr bauer holds a bsc in biology and a ba in economics from duke university and an mba from harvard business school executive committee member ingrid boyes senior vice president human resources ingrid boyes has more than  years of human resources and senior leadership experience across the insurance banking and biotech industries prior to myokardia ms boyes was vice president and head of human resources for global product development at roche in this role she was responsible for leading the human resources strategy globally for that function previously she was at genentech where she held positions of increasing responsibility including director of corporate staffing and diversity she was also senior director of human resources for technical operations and prior to that held a similar role leading human resources for north america commercial operations  ms boyes holds a bs from the university of san francisco and an mba from notre dame de namur university executive committee member   joseph lambing phd senior vice president nonclinical and pharmaceutical development joe lambing phd has more than  years of drug development experience in the areas of cardiovascular disease inflammation and oncology during his career dr lambing has contributed to numerous nda and ind filings for more than a dozen new chemical entities as well as numerous filings to support a variety of clinical trials in other countries prior to joining myokardia he was senior vice president of development for portola pharmaceuticals where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in  prior to portola dr lambing served as director of drug safety and disposition for millennium pharmaceuticals’ san francisco site and director of dmpk and toxicology at cor therapeutics dr lambing holds a bs in chemistry and a phd in biochemistry from the university of missouri and was a postdoctoral fellow at the university of california san diego executive committee member robert s mcdowell phd senior vice president of drug discovery robert mcdowell has  years of experience discovering small molecule drugs in cardiovascular disease inflammation and oncology with seven compounds advancing into clinical trials prior to joining myokardia dr mcdowell led drug discovery at v biosciences advancing the companys lead program into development he previously served as vice president of research at sunesis pharmaceuticals where he oversaw drug discovery translational research and manufacturing functions dr mcdowell led the structural chemistry group at axys pharmaceuticals before joining axys dr mcdowell was a senior scientist at genentech where he developed successful strategies for peptidomimetic design dr mcdowell has authored more than  peerreviewed manuscripts and is an inventor on more than  issued us patents dr mcdowell holds a bs in chemistry and physics from butler university and a phd in chemistry from the university of california at berkeley executive committee member lisa alaimo vice president program team leader lisa alaimo has more than  years of research and development experience across a range of biotech companies managing products at various stages of development ms alaimo currently manages the company’s dilated cardiomyopathy program as well as myokardia’s collaboration with sanofi the alliance of the two companies one of the largest research and development commitments in genetic cardiomyopathy encompasses three major development programs at myokardia ms alaimo has served in project and strategic product development leadership roles at portola pharmaceuticals cor therapeutics and millennium pharmaceuticals  ms alaimo holds a bs in genetics and biochemistry from university of california davis radhika tripuraneni md vice president medical affairs radhika tripuraneni md has more than a decade of experience across multiple therapeutic areas including rare and cardiovascular diseases prior to myokardia dr tripuraneni was vice president medical affairs at synageva biopharma later alexion pharmaceuticals where she worked closely with physicians medical societies and patient groups to further disease awareness and support clinical trial enrollment and execution previously she was a cardiovascular medical director at gilead sciences and served as global medical director and global medical affairs lead for two therapeutic areas at genzyme  dr tripuraneni holds undergraduate degrees in business administration and liberal arts and an md degree from the university of missouri she did her surgical internship at beth israel deaconess medical center in boston a major teaching hospital of harvard medical school she earned a master’s of public health degree from harvard university  myok profile  myokardia inc stock  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listentop economists debate state of labor marketyahoo finances nicole sinclair moderates a panel of leading economists at the state of the labor market summitmyokardia inc myoknasdaqgs  nasdaqgs delayed price currency in usdadd to watchlist at close pm edt  after hours pm edtpeople also watchvygrctmxwvergnxnbrvsummaryconversationsstatisticsprofilefinancialsoptionsholdershistorical dataanalystsmyokardia inc allerton avenuesouth san francisco ca united stateshttpwwwmyokardiacomsector industry full time employees key executivesnametitlepayexercisedagemr tassos anastasios gianakakoschief exec officer pres and directorknamr jake b bauerprincipal financial officer sr vp of fin  corp devel and assistant secknadr marc semigran mdchief medical officerknadr charles j homcy mdadvisorknadr leslie leinwand phdcofoundernananaamounts are as of december   and compensation values are for the last fiscal year ending on that date pay is salary bonuses etc exercised is the value of options exercised during the fiscal year currency in usddescriptionmyokardia inc a clinical stage biopharmaceutical company engages in discovering developing and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases its lead product candidate is myk an orallyadministered small molecule that is in phase ii clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy hcm the company also develops myk an orallyadministered small molecule that treats genetic dilated cardiomyopathy dcm by restoring normal contractility in the diseased dcm heart in addition it develops hcm a product candidate to reduce cardiac muscle contractility to normal levels in hcm patients dcm a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic dcm patients through a different mechanism than that of myk and lus a product candidate which is intended to counteract a muscle disruption that results in impaired relaxation of the heart the company has a strategic collaboration with sanofi sa for the research development and commercialization of pharmaceutical products to treat prevent and diagnose hcm and dcm as well as additional indications myokardia inc was founded in  and is headquartered in south san francisco californiacorporate governancemyokardia inc’s iss governance qualityscore as of july   is  the pillar scores are audit  board  shareholder rights  compensation corporate governance scores courtesy of institutional shareholder services iss scores indicate decile rank relative to index or region a decile score of  indicates lower governance risk while a  indicates higher governance riskyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated myok news  myokardia inc company news  press releases  marketwatch bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close myokardia inc nasdaq myok go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus myokardia inc after hours  quotes are delayed by  min jul    pm myok quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   newslatestcompanyusmyok marketwatch news on myok myokardia initiated at outperform at credit suisse  am nov    ciara linnane newsnonmarketwatchcompanyusmyok other news on myok myokardia brings hope to hypertrophic cardiomyopathy  am july    seeking alpha myokardia does this small biotech stock belong on your buy list  am june    seeking alpha myokardias myok ceo tassos gianakakos on q  results  earnings call transcript  pm may    seeking alpha three top picks in smaller pharma  am may    barronscom hershey trust co buys momo vipshop holdings ametek sells sage therapeutics jd   pm april    gurufocuscom k myokardia inc  pm march    edgar online  edg  q k myokardia myok presents at cowen and company th annual health care conference  pm march    seeking alpha sanofi reups with myokardia in cardiomyopathy m milestone triggered  am jan    seeking alpha hottest manufacturing stocks now – spcb cala mtp ocrx  am dec    investorplacecom myokardia myok investor presentation  am dec    seeking alpha biggest movers in manufacturing stocks now – sndx dmpi reta crbp  pm dec    investorplacecom myokardia earns m milestone from sanofi for myk ind  am dec    seeking alpha hottest manufacturing stocks now – phmd caas albo cfrx  pm nov    investorplacecom biggest movers in manufacturing stocks now – scmp ebio rvnc agtc  pm nov    investorplacecom q myokardia inc  pm nov    edgar online  edg  q k biotech snapshot myokardia has a heart of gold  am oct    seeking alpha hottest manufacturing stocks now – prqr loxo kmph fcau  pm oct    investorplacecom insider update facebook axalta versartis  pm oct    gurufocuscom insiderinsightscom daily round up  lands end bancorp hyster yale materials handling  pm oct    seeking alpha  signs invitaes best days are ahead  pm sept    motley fool loading more headlines newspressreleasecompanyusmyok press releases on myok myokardia reports first quarter  financial results and operational progress  pm may    globenewswire investor network myokardia inc to host earnings call  pm may    accesswire myokardia to announce first quarter  financial results and host conference call on tuesday may    am may    globenewswire myokardia appoints david meeker md to board of directors  am april    globenewswire myokardia appoints kim popovits and wendy yarno to board of directors  am march    globenewswire myokardia reports fourth quarter and full year  financial results and operational progress  am march    globenewswire myokardia to present at cowen and company th annual health care conference  am feb    globenewswire first subjects dosed in phase  study of dilated cardiomyopathy candidate myk  am feb    globenewswire myokardia announces appointment of june lee md as chief operating officer and radhika tripuraneni md as vice president medical affairs  am feb    globenewswire myokardia announces advancement to next phase of global collaboration with sanofi  am jan    globenewswire myokardia to present at  bmo capital markets healthcare conference  am dec    globenewswire blog coverage myokardia announced receipt of payment from sanofi  am dec    accesswire myokardia announces receipt of milestone payment from sanofi for dcm candidate myk  am dec    globenewswire myokardia announces appointment of marc semigran md as chief medical officer  am dec    globenewswire myokardia announces exploratory digital health substudy as part of pioneerhcm trial of myk in symptomatic obstructive hypertrophic cardiomyopathy patients  am nov    globenewswire myokardia announces presentations at american heart association scientific sessions   am nov    globenewswire myokardia announces dosing of first patient in phase  pioneerhcm study of myk in symptomatic obstructive hypertrophic cardiomyopathy  am nov    globenewswire myokardia to present at two upcoming investor conferences in november  am oct    globenewswire myokardia announces closing of public offering of common stock including full exercise of option to purchase additional shares  pm oct    globenewswire myokardia announces pricing of proposed public offering of common stock  pm sept    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthis social network ranks as the worst for young people’s mental health it’s not facebook pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pthis is the worst mistake people make at work pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pwatch out for these surprise charges at the er pthe open road or the open skies millennials choose the former phow an online wedding registry in my name appeared out of thin air pdon’t have a college degree these are the industries with the bestpaid jobs pthe highest paid athletes in the world in one chart phow to teach your kids to be better with money than you are pbacktoschool shopping goes mainstream with deals on eyewear fitness apparel and kitchen appliances psamsung posts record profits on back of strong galaxy s sales pthe dark side of cruises pfor transgender americans workplace discrimination isn’t limited to the military pscaramucci on washington back stabbers ‘i’m more of a frontstabbing person’ pfacebook keeps warning about growth but growth doesn’t stop pfacebook heads toward  billion market cap after earnings pfoxconn pledges to build  billion stateoftheart electronics plant in wisconsin pgraham says trump is showing weakness in unilateral public spat with sessions loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  myokardia myokardia inc is pioneering a precision medicine approach to discover develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases our initial focus is on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction  about cardiomyopathies heartbeats a conversation with the hypertrophic cardiomyopathy experts listen to the podcast news  events may   myokardia reports first quarter  financial results and operational progress link april   myokardia appoints david meeker md to board of directors link march   myokardia appoints kim popovits and wendy yarno to board of directors link march   myokardia reports fourth quarter and full year  financial results and operational progress link february   first subjects dosed in myokardia phase  study of dilated cardiomyopathy candidate myk link bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one